Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 164

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 7
Chunk 164
---
0%, inclusive of a 5.3% favorable effect of currency translation, due primarily to deprioritization of the nutraceuticals portfolio in addition to a 0.9% unfavorable impact from exited products. 

•Women's Health: Net sales of $29.9 million decreased 7.1%, inclusive of a 4.6% favorable effect of currency translation, due primarily to supply constraints that have since been resolved. 

•Oral Care: Net sales of $23.9 million increased 2.6%, inclusive of a 5.1% favorable effect of currency translation, due primarily to lower net sales of store brand products and a 1.6% unfavorable impact from exited products.

•Digestive Health and Other: Net sales of $22.5 million decreased 26.1%, inclusive of a 4.0% favorable effect of currency translation, primarily due to divested businesses, including HRA Pharma Rare Diseases, and exited products.

49

Perrigo Company plc - Item 2CSCI

Operating income decreased $11.5 million, or 23.5%, due primarily to:

•$13.5 million decrease in gross profit due primarily to lower net sales volumes flow through, as well as $7.4 million from the impact of divested businesses and exited product lines. These factors were partially offset by $9.5 million increase from favorable currency translation. Gross profit as a percentage of net sales decreased 130 basis points compared to the prior year due to the same factors impacting gross profit.

•$2.0 million decrease in operating expenses driven by the absence of the prior year impairment charges of $16.2 million recognized as part of the assets held for sale of the Hospital & Specialty Business, and decreased administrative costs due primarily to lower variable employee expenses, partially offset by the absence of the prior year gain on the sale of branded products. 

Nine Month Comparison

 Nine Months Ended(in millions, except percentages)September 27, 2025September 28, 2024Net sales$1,255.1 $1,285.5 Gross profit$564.0 $594.2 Gross profit %44.9 %46.2 %Operating income$136.2 $65.1 Operating income %10.9 %5.1 %

Net sales decreased $30.4 million, or 2.4%, due primarily to: